Multi-dimensional proteomic profiling identifies proteins linked to injury severity in pediatric sTBI, suggesting new therapeutic targets.
These findings identify differentially expressed plasma proteins and enriched signaling pathways associated with clinical features, providing novel insights into pediatric sTBI pathophysiology. The identification of IL-6 as a central hub protein and the correlation of specific pathways with injury severity, metabolic dysfunction, and coagulopathy suggest potential targets for therapeutic intervention and prognostic biomarker development. This proteomic approach advances our understanding of the complex molecular cascades underlying pediatric sTBI and may inform precision medicine strategies for improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Cela et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: